Zacks Research Brokers Raise Earnings Estimates for Omnicell

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research lifted their Q4 2024 EPS estimates for Omnicell in a note issued to investors on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.29 for the quarter, up from their previous forecast of $0.28. The consensus estimate for Omnicell’s current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

Several other research firms also recently weighed in on OMCL. Barclays raised their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Bank of America reaffirmed a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Finally, Wells Fargo & Company lifted their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $52.00.

Omnicell Trading Up 2.3 %

NASDAQ:OMCL opened at $45.32 on Monday. The company’s 50-day moving average price is $46.17 and its 200-day moving average price is $40.56. The company has a market cap of $2.10 billion, a P/E ratio of -116.20, a P/E/G ratio of 34.96 and a beta of 0.78. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares in the last quarter. 1620 Investment Advisors Inc. lifted its stake in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the last quarter. Headlands Technologies LLC purchased a new position in Omnicell in the second quarter worth approximately $104,000. Summit Global Investments purchased a new position in Omnicell in the third quarter worth approximately $221,000. Finally, QRG Capital Management Inc. purchased a new position in Omnicell in the third quarter worth approximately $231,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.